AseraCare: The Evidence Behind the Hospice Signature

The AseraCare hospice fraud case challenged Medicare billing for patients the government alleged did not qualify for hospice. AseraCare operated a national hospice chain and told Medicare those patients were terminally ill. Former employees started the qui tam case, and the government joined it. The case ended in a settlement in 2020.

The allegations put a familiar hospice fraud question inside the company: what happens when pressure to admit patients reaches the people deciding whether they qualify?

What the Government Challenged at AseraCare

The government alleged that AseraCare admitted patients whose records did not support a terminal prognosis, then submitted Medicare claims for their care. It described aggressive monthly intake quotas and a business culture that discouraged meaningful physician involvement in eligibility decisions.

Medicare hospice eligibility depends on a physician’s judgment that the patient’s life expectancy is six months or less if the illness follows its normal course. Clinical information supporting that prognosis belongs with the certification in the medical record. Continued care requires recertification. That makes admission and recertification decisions recurring points where the medical judgment and the business’s financial interest meet.

The payment structure explains the pressure. Routine home care pays by the enrolled day, including days without a visit. Costs tend to be highest around admission and death, with a less expensive stretch between them. A long stay can keep generating revenue while requiring comparatively little care. In the government’s account, AseraCare pursued admissions because they were financially attractive, while taxpayers paid for hospice claims the government said were unsupported.

Every extra visit costs money, while routine payment arrives by the day. Quality, Reputation, and Reimbursement Design in the Hospice Industry, a 2026 Kansas State University working paper, modeled California hospice competition and found that stronger reputation effects improved care quality, measured through visits per patient per day. Good care could attract future patients. The allegations against AseraCare concerned a more immediate way to increase revenue: admitting patients whose records did not support hospice eligibility.

AseraCare’s Statistical Sample and Trial Extrapolation in Hospice

The AseraCare statistical sample was intended to let the government use a trial over selected hospice patients to pursue claims across a larger population. Extrapolation meant carrying findings from the sample to additional claims through statistical analysis.

The Eleventh Circuit’s account identifies approximately 2,180 patients for whom AseraCare had billed Medicare for at least 365 continuous days of hospice care. The government drew a sample of 223 patients. Its medical expert identified 123 patients in that sample whom he considered ineligible at the relevant times. Those patients became the group examined at trial.

The Trial Split the Certification From the Company’s Knowledge

At AseraCare’s request, the trial court separated whether the claims were false from whether the company knew they were false. Some employee testimony about certification practices reached the jury only as background. Other evidence was held for a later phase. The first phase became a contest between doctors reviewing the patient records.

The jury found false claims involving 104 patients. The judge then ordered a new trial after finding the jury instructions inadequate, and later ruled for AseraCare without another trial. In September 2019, the Eleventh Circuit set aside that ruling and required the court to consider all the government’s evidence together. The jury finding stayed set aside, but AseraCare’s win was overturned too.

AseraCare, Reasonable Physicians Who Disagree, and Objective Falsity

AseraCare’s objective falsity standard focused on verifiable flaws in the certification process. The Eleventh Circuit identified evidence that could show how a certification went wrong, including a signature given without reviewing the patient’s condition.

A physician might sign without reviewing the records or otherwise learning the patient’s condition. The physician might certify a prognosis they did not actually believe. The certification might rely on information the physician knew, or had reason to know, was wrong. Expert evidence could also show that no reasonable physician would reach the terminal prognosis from the available medical information.

Those examples move the inquiry into the work behind the signature. What did the physician receive? What did the physician review? Did the signed prognosis reflect the judgment the physician actually made? An insider in clinical services, intake or billing may have seen that process from a different position than someone reading the finished chart.

What Evidence Is Needed to Prove Fraud?

In AseraCare, the appeals court required the government to connect evidence of improper certification practices to the particular claims being challenged. A specific patient’s record, certification and Medicare claim were the connection the government had to make.

The court’s account of the employee testimony and proposed audit evidence shows what had been lost in the trial’s division. A former clinical-services director testified that she usually gave a certifying physician papers to sign without clinical information. The government also planned to present internal and external audit criticism that medical directors were insufficiently involved and did not consistently receive medical information before certifying patients.

The government also planned testimony from a former physician that employees proceeded with claims despite his judgment that certain patients did not qualify.

Certifications Signed Before the Physician Reviewed the Patient

One whistleblower complaint alleged that managers obtained blank physician-signed terminal-illness forms and used them to bill Medicare for ineligible patients. A separate complaint described a nurse raising concerns about patients who did not qualify and receiving this instruction:

The alleged instruction put admission ahead of resolving the nurse’s concern. The blank-form allegation put a signature ahead of the completed certification. Both allegations explain why the order of events matters: the assessment, the information sent to the physician, the signature and the claim that followed.

A Review Meeting Reduced to Reading Names

Another whistleblower complaint alleged that patient names were read at interdisciplinary team meetings, a designated person answered “no change,” and the meeting moved to the next patient. It also alleged that a medical director overrode requests to decertify patients.

That complaint described later changes to treatment records as well:

These allegations reach different parts of the path from the patient record to the Medicare claim. A review reduced to reading names and a treatment entry added weeks later can leave the next person relying on a record that conceals what happened.

The Census and the Cap Pulled on Clinical Decisions

AseraCare’s whistleblowers also alleged that financial targets influenced admissions and discharges. One complaint alleged instructions to admit ineligible patients to avoid repaying money above Medicare’s aggregate cap. Another alleged orders to discharge patients with longer stays regardless of their actual condition or prognosis, also to avoid cap exposure.

The aggregate cap calculation ties a provider’s annual Medicare payment ceiling to its beneficiary count, with allocation rules for patients served across hospices and years. Additional qualifying beneficiary shares can raise that ceiling. That helps explain why pressure could push toward keeping a patient enrolled in one circumstance and seeking new admissions or discharges in another.

Those decisions reached patients and families too. A complaint alleged that training instructed employees to secure hospice elections while withholding information that would give patients and families a real choice. The alleged sales pressure shaped both the claim Medicare paid and the care the patient accepted.

The Settlement Followed the Reversal

The parties reached their settlement agreement in February 2020, and the trial court entered its final dismissal on February 28. The agreement ended the case after the appeal reopened consideration of the full evidence.

Why the Work Behind the Signature Still Matters

AseraCare makes the clinical process central to an eligibility case: the information supplied, the judgment exercised and the claim submitted. The person who saw a nurse’s objection overridden or a certification signed before the physician reviewed the patient may know something the completed chart leaves out.

In the Care Alternatives case, another appeals court took a different approach: an expert’s challenge to the support for a hospice certification could create a question for a jury. We assess those differences with you and bring in whistleblower lawyers who know the hospice evidence.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

When You Saw How the Certification Was Made

If you worked in hospice intake, clinical services or billing and saw patient assessments give way to admission targets, speak to our whistleblower experts about what happened behind the signatures. We build the case with you around the clinical decisions, the company’s instructions and the Medicare claims, and bring in hospice fraud whistleblower lawyers who understand disputed eligibility. We stay beside you from that first account through the case.